Mission Bio Raises $70M in Series C Funding Led by Novo Holdings to Accelerate Development of Cancer Therapies with Single-cell Multi-omics

SOUTH SAN FRANCISCO, Calif. (August 13, 2020) Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced $70 million in its Series C financing led by Novo Growth, the growth equity arm of Novo Holdings. Soleus Capital also joins the round, along with earlier investors Mayfield, Cota, and Agilent, bringing the company’s total funding to more than $120 million. To support Mission Bio’s rapid growth, the funds will scale its single-cell multi-omics technology, the Tapestri® Platform, to expand the company’s reach in more effective clinical trials for novel cancer treatments, as well as characterization for cell and gene therapy.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH